Quintero SI

Idioma: Ingles.
Referencias bibliográficas: 10
Paginas: 32-33
Archivo PDF: 41.15 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36(5Suppl.1): S35-46.

2. Fried MW, Shiffman ML, Reddy KR, et al. Peg-interferon alfa 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

3. Keating GM, Curran MP. Peg-interferon alfa-2a (40KD) plus ribavirin. A review of its use in the management of chronic hepatitis C. Drugs 2003; 63: 701-30.

4. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10–12, 2002. Hepatology 2002; 36(Suppl.1): S3-S15.

5. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21): 1485-92.

6. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.

7. Olaso Peiró V, Córdoba Cortijo J, Prieto Castillo M. Treatment de la hepatitis crónica C. Rev Esp Enf Digest 1997; 89: 621-37.

8. EASL Internatinal Consensus Conference on Hepatitis C. Paris 27–28 February 1999. Consensus Statement. J Hepatol 1999; 30: 956-61.

9. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology 2002; 36( Suppl.1): S128–134.

10. Alberti L. Nengegnú. Management of Hepatitis C. J Hepatol 2003; 38: S104-S118.